Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostaglandin reductase 2 (PTGR2) is an NAD(P)H-dependent enzyme that catalyzes the reduction of 15-keto-prostaglandins (including 15-keto-PGE2) to 13,14-dihydro-15-keto-prostaglandins, thus regulating the levels of active prostaglandins in cells[2][7]. It is expressed in various tissues and plays roles in endogenous prostaglandin catabolism and in modulating biological processes such as cell proliferation and PPARγ signaling[1][2][7]. Alterations in its expression or activity have been implicated in diseases such as cancer and inflammatory conditions, where prostaglandin signaling impacts cell fate and immune responses[1][2].
Enzymatic reduction of 15-keto-prostaglandins to inactive metabolites Modulation of PPARγ signaling via metabolite control
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin reductase 2 (PTGR2).